Ignite Creation Date:
2025-12-24 @ 5:03 PM
Ignite Modification Date:
2025-12-30 @ 6:03 AM
Study NCT ID:
NCT00722150
Status:
COMPLETED
Last Update Posted:
2011-01-25
First Post:
2008-07-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Artemisinin Resistance in Cambodia II
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D016778', 'term': 'Malaria, Falciparum'}], 'ancestors': [{'id': 'D008288', 'term': 'Malaria'}, {'id': 'D011528', 'term': 'Protozoan Infections'}, {'id': 'D010272', 'term': 'Parasitic Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D000096724', 'term': 'Mosquito-Borne Diseases'}, {'id': 'D000079426', 'term': 'Vector Borne Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077332', 'term': 'Artesunate'}], 'ancestors': [{'id': 'D037621', 'term': 'Artemisinins'}, {'id': 'D017382', 'term': 'Reactive Oxygen Species'}, {'id': 'D005609', 'term': 'Free Radicals'}, {'id': 'D007287', 'term': 'Inorganic Chemicals'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D012717', 'term': 'Sesquiterpenes'}, {'id': 'D013729', 'term': 'Terpenes'}, {'id': 'D006838', 'term': 'Hydrocarbons'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 143}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2008-07'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2011-01', 'completionDateStruct': {'date': '2009-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2011-01-24', 'studyFirstSubmitDate': '2008-07-23', 'studyFirstSubmitQcDate': '2008-07-23', 'lastUpdatePostDateStruct': {'date': '2011-01-25', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2008-07-25', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2009-08', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Primary clinical outcome is cure (Adequate Clinical and Parasitological Response - ACPR as defined by WHO criteria) on Day 28 and 42', 'timeFrame': 'Day 28 and 42'}, {'measure': 'Safety and tolerability of oral artesunate', 'timeFrame': 'Up to 42 days'}], 'secondaryOutcomes': [{'measure': 'Secondary outcome measures are time until parasite, fever, and gametocyte clearance (PCT, FCT, and GCT).', 'timeFrame': 'Day 3'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Artesunate', 'Plasmodium Falciparum', 'Cambodia'], 'conditions': ['Falciparum Malaria']}, 'referencesModule': {'references': [{'pmid': '21603629', 'type': 'DERIVED', 'citation': 'Bethell D, Se Y, Lon C, Tyner S, Saunders D, Sriwichai S, Darapiseth S, Teja-Isavadharm P, Khemawoot P, Schaecher K, Ruttvisutinunt W, Lin J, Kuntawungin W, Gosi P, Timmermans A, Smith B, Socheat D, Fukuda MM. Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial. PLoS One. 2011;6(5):e19283. doi: 10.1371/journal.pone.0019283. Epub 2011 May 13.'}, {'pmid': '21070142', 'type': 'DERIVED', 'citation': 'Bethell D, Se Y, Lon C, Socheat D, Saunders D, Teja-Isavadharm P, Khemawoot P, Darapiseth S, Lin J, Sriwichai S, Kuntawungin W, Surasri S, Lee SJ, Sarim S, Tyner S, Smith B, Fukuda MM. Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. Clin Infect Dis. 2010 Dec 15;51(12):e105-14. doi: 10.1086/657402. Epub 2010 Nov 11.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine the impact of varying doses of artesunate on treatment outcome and whether higher doses of artesunate can overcome the problem of compromised artemisinin sensitivity in the region.\n\nTo determine the safety and tolerability of this previously untested experimental high dose (6 mg/Kg/D X 7 day, total 42 mg/Kg) artesunate monotherapy regimen.', 'detailedDescription': 'A total of 150 volunteers with acute uncomplicated falciparum malaria will be randomly assigned one of 3 arms to be treated with artesunate monotherapy for 7 days at a ratio of 2:1:2.\n\nArm 2 serves as a control and will serve as a bridge to the ARC 1 study performed in 2006/2007. Patients in Arm 1 will receive a relatively low "standard" dose, and patients in Arm 2 will receive the intermediate dose of 4 mg/kg that was used in the ARC1 study. Patients in Arm 3 will receive an experimental "high-dose" regimen. Currently available safety data extends to subjects who have received the 28 mg/Kg total dose over 7 days and to another study administering 8 mg/Kg/day for 3 days (total dose 24 mg/Kg). Subjects randomized into this study\'s \'high-dose\' Arm 3 will, therefore, receive a total dose that is higher than has been previously studied in humans.\n\nThe study design will be based on the WHO recommendations for the \'Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria\' (WHO, 2003).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Acute symptomatic falciparum malaria infection as determined by malaria smear with a parasite density of 1000 to 200,000 asexual parasites/Micro-liter as determined on the thick/thin screening smear with fever (defined as ≥ 37.5ºC), or reported history of fever within the last 48 hours.\n2. Age: 18-65 years old\n3. All females between the age of 18 and 50 are required to have a negative human chorionic gonadotropin (hCG) pregnancy test (urine). All females of childbearing potential (not surgically sterile, or less than two years menopausal) are required to use an acceptable method of contraception, such as implant, injectable, or oral contraceptive(s), if possible with additional barrier contraception, intrauterine device, sexual abstinence, or vasectomized partner, throughout the study.\n4. Written informed consent obtained\n5. Willing to stay under close medical supervision for the study duration of 42 days\n6. Otherwise healthy Out-patients\n\nExclusion Criteria:\n\n1. Pregnant women, nursing mothers, or women of childbearing potential who do not use an acceptable method of contraception (as described in Inclusion Criteria, # 3)\n2. Mixed malaria infection on admission by malaria smear\n3. A previous history of intolerance or hypersensitivity to the study drug artesunate or to drugs with similar chemical structures, such as artemether, artemisinin or dihydroartemisinin\n4. History of malaria drug therapy administered in the past 30 days\n5. Previous participation in this trial, or participation in any other studies involving investigational or marketed products, concomitantly or within 30 days prior to entry in the study\n6. History of significant cardiovascular, liver or renal functional abnormality or any other clinically significant illness, which in the opinion of the investigator would place them at increased risk.\n7. Symptoms of severe vomiting (no food or inability to take food during the previous 8 hours).\n8. Signs or symptoms of severe malaria (adapted from WHO recommendations (2003): prostration, impaired consciousness, respiratory distress, convulsions, systolic blood pressure \\< 70 mm Hg, abnormal bleeding, severe anemia with hemoglobin \\< 8 g/dL or HCT \\< 24%, hyperparasitemia at \\> 4% parasitized red blood cells).\n9. Unable and/or unlikely to comprehend and/or follow the protocol'}, 'identificationModule': {'nctId': 'NCT00722150', 'acronym': 'ARC II', 'briefTitle': 'Artemisinin Resistance in Cambodia II', 'organization': {'class': 'OTHER_GOV', 'fullName': 'Armed Forces Research Institute of Medical Sciences, Thailand'}, 'officialTitle': 'Artemisinin Resistance in Cambodia II', 'orgStudyIdInfo': {'id': 'WRAIR 1396'}, 'secondaryIdInfos': [{'id': 'HSRRB number A-14479'}, {'id': 'WHO RPC252'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Arm 1', 'description': 'Oral Artesunate ("standard" dose)', 'interventionNames': ['Drug: Artesunate']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Arm 2', 'description': 'Oral Artesunate ("ARC1" dose)', 'interventionNames': ['Drug: Artesunate']}, {'type': 'EXPERIMENTAL', 'label': 'Arm 3', 'description': 'Oral Artesunate (experimental "high" dose)', 'interventionNames': ['Drug: Artesunate']}], 'interventions': [{'name': 'Artesunate', 'type': 'DRUG', 'description': '2 mg/kg/day x 7 days', 'armGroupLabels': ['Arm 1']}, {'name': 'Artesunate', 'type': 'DRUG', 'description': '4 mg/kg/day x 7 days', 'armGroupLabels': ['Arm 2']}, {'name': 'Artesunate', 'type': 'DRUG', 'description': '6 mg/kg/day x 7 days', 'armGroupLabels': ['Arm 3']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Sam Lot District', 'state': 'Battambang', 'country': 'Cambodia', 'facility': 'Tasanh Health Center'}], 'overallOfficials': [{'name': 'Delia Bethell, BM BCh', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Armed Forces Research Institute of Medical Sciences (AFRIMS)'}, {'name': 'Socheat Duong, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'National Center for Parasitology, Entomology and Malaria Control'}, {'name': 'Se Youry, M.D., M.P.H.M.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Armed Forces Research Institute of Medical Sciences (AFRIMS)'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Armed Forces Research Institute of Medical Sciences, Thailand', 'class': 'OTHER_GOV'}, 'collaborators': [{'name': 'World Health Organization', 'class': 'OTHER'}, {'name': 'Bill and Melinda Gates Foundation', 'class': 'OTHER'}], 'responsibleParty': {'oldNameTitle': 'Mark Fukuda, M.D., LTC, MC', 'oldOrganization': 'Armed Forces Research Institute of Medical Sciences (AFRIMS)'}}}}